BACKGROUND: The inflammatory background of patients influences the process of alloimmunization against red blood cell antigens. Proof of this statement to clinical practice is still lacking. OBJECTIVE: The aim of this study was to verify whether factors related to disease severity and inflammatory status of cancer patients can predict alloimmunization. METHODS: This was a case-control study in which alloimmunized oncologic patients treated between 2009 and 2012 were compared with a non-alloimmunized control group regarding the severity of the disease (metastasis/performance status/body mass index) and C-reactive protein levels. RESULTS: The groups did not differ significantly in terms of C-reactive protein, Eastern Cooperative Oncology Group (ECOG)/Karnofsky performance status, presence of metastasis and body mass index. CONCLUSION: It is not possible to predict alloimmunization in cancer patients based on severity of illness and inflammatory markers. Strategies of screening patients by phenotyping blood based on these criteria are not justified.
BACKGROUND: The inflammatory background of patients influences the process of alloimmunization against red blood cell antigens. Proof of this statement to clinical practice is still lacking. OBJECTIVE: The aim of this study was to verify whether factors related to disease severity and inflammatory status of cancerpatients can predict alloimmunization. METHODS: This was a case-control study in which alloimmunized oncologic patients treated between 2009 and 2012 were compared with a non-alloimmunized control group regarding the severity of the disease (metastasis/performance status/body mass index) and C-reactive protein levels. RESULTS: The groups did not differ significantly in terms of C-reactive protein, Eastern Cooperative Oncology Group (ECOG)/Karnofsky performance status, presence of metastasis and body mass index. CONCLUSION: It is not possible to predict alloimmunization in cancerpatients based on severity of illness and inflammatory markers. Strategies of screening patients by phenotyping blood based on these criteria are not justified.
Authors: Scott T Miller; Hae-Young Kim; Debra L Weiner; Carrie G Wager; Dianne Gallagher; Lori A Styles; Carlton D Dampier; Susan D Roseff Journal: Transfusion Date: 2012-07-13 Impact factor: 3.157
Authors: Steven C Kao; Janette Vardy; Rozelle Harvie; Mark Chatfield; Nico van Zandwijk; Stephen Clarke; Nick Pavlakis Journal: Support Care Cancer Date: 2012-08-31 Impact factor: 3.603
Authors: Jeanne E Hendrickson; Maxime Desmarets; Seema S Deshpande; Traci E Chadwick; Christopher D Hillyer; John D Roback; James C Zimring Journal: Transfusion Date: 2006-09 Impact factor: 3.157
Authors: Jeanne E Hendrickson; Traci E Chadwick; John D Roback; Christopher D Hillyer; James C Zimring Journal: Blood Date: 2007-06-25 Impact factor: 22.113
Authors: Carla L Dinardo; Shannon Kelly; Marcia R Dezan; Ingrid H Ribeiro; Shirley L Castilho; Luciana C Schimidt; Maria do C Valgueiro; Liliana R Preiss; Brian Custer; Ester C Sabino; Connie M Westhoff Journal: Transfusion Date: 2019-08-13 Impact factor: 3.157